Habib Maria, Azam Khalil Kheyal, Tayyab Zain, Saeed Usmani Afshan, Ahmed Yashfeen, Shah Ansab, Ali Syed Aamir
Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.
Cureus. 2024 Jul 28;16(7):e65580. doi: 10.7759/cureus.65580. eCollection 2024 Jul.
It is very controversial whether appendectomy should be performed as a routine part of the staging procedure for mucinous borderline ovarian tumours (mBOTs) or not, as the involvement of the appendix in women undergoing surgery for mBOTs and the exact magnitude of the benefit of appendectomy are unclear. This study was conducted to determine the frequency of appendiceal involvement in patients of mBOTs and morbidity associated with surgery and to evaluate recurrence-free survival after surgery.
This retrospective cohort study was conducted at a cancer centre from January 2008 to December 2022 (15 years). The hospital database was searched for patients whose final diagnosis was mBOTs. All women who have been operated for mBOTs were included in the study. Descriptive analysis was performed for study variables. The survival curve was calculated according to the Kaplan-Meier method.
Ninety cases whose final diagnosis was mBOTs were identified from the Cancer Registry. Of those, 39 cases were excluded as they did not fulfil the inclusion criteria. Fifty-one patients were finally selected for the study. Of the 51 patients, appendectomy was not performed in eight patients, and the reason was not mentioned in the hospital record. The appendix was macroscopically abnormal in only two patients. None of the patients was diagnosed with mucinous borderline tumours of the appendix in our study. The appendectomy itself was not associated with any complications. Only one patient with mBOT had recurrence after four months of surgery, which was surgically treated and no patient died during the median follow-up of 36 months.
If the appendix is grossly normal looking, then appendectomy can be omitted in surgery of mBOTs. mBOTs have good recurrence free and overall survival outcomes post surgery.
对于阑尾切除术是否应作为黏液性交界性卵巢肿瘤（mBOTs）分期手术的常规部分，目前存在很大争议，因为mBOTs手术患者中阑尾受累情况以及阑尾切除术的确切获益程度尚不清楚。本研究旨在确定mBOTs患者阑尾受累的频率、手术相关并发症，并评估术后无复发生存率。
本回顾性队列研究于2008年1月至2022年12月（15年）在一家癌症中心进行。在医院数据库中搜索最终诊断为mBOTs的患者。所有接受mBOTs手术的女性均纳入研究。对研究变量进行描述性分析。根据Kaplan-Meier方法计算生存曲线。
从癌症登记处确定了90例最终诊断为mBOTs的病例。其中，39例因不符合纳入标准而被排除。最终选择51例患者进行研究。在这51例患者中，8例未进行阑尾切除术，医院记录中未提及原因。仅2例患者的阑尾在宏观上异常。在我们的研究中，没有患者被诊断为阑尾黏液性交界性肿瘤。阑尾切除术本身未引起任何并发症。仅1例mBOT患者术后4个月复发，接受了手术治疗，在36个月的中位随访期内无患者死亡。
如果阑尾外观大体正常，那么在mBOTs手术中可省略阑尾切除术。mBOTs术后具有良好的无复发生存率和总生存率。
